







Carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis

Submission date 08/10/2018	Recruitment status No longer recruiting	 Prospectively registered
Registration date 10/10/2018	Overall study status Completed	 Protocol added
Last Edited 15/12/2022	Condition category Digestive System	 SAP not yet added
		 Results not yet added and study completed for less than 1 year
		 Raw data not yet added
		 Study completed

Plain English Summary

Background and study aims

People with long-standing liver disease called cirrhosis (scarring of the liver) can develop enlargement of veins in the gullet (food pipe) known as 'oesophageal varices'. Patients with medium to large oesophageal varices have a 1 in 3 chance of these veins bleeding. In very severe cases, this could result in death. It is therefore important to lower the risk of this bleeding. At present, all people with medium to large oesophageal varices are offered one of two treatments to lower the risk of bleeding either beta-blockers or variceal band ligation. Some research studies suggest that banding may be more effective than beta-blockers in lowering the risk of variceal bleeding, but other studies suggest that this is not the case. However, all of these studies have been small and we still do not know which treatment is best. We need to do a study to compare carvedilol with banding in people with cirrhosis who have medium to large varices that have never bled. Therefore the aim of the trial is to see which intervention works better. This will be done by observing which treatment is effective in stopping the bleeding of varices in the first 12 months after randomisation.

Who can participate?

Adults who have been diagnosed with liver cirrhosis who have medium or large varices that have not bled

What does the study involve?

Participants will be randomly allocated to receive either beta-blocker drugs (carvedilol) or variceal banding. Participants will be on the study for 12 months duration and if randomised to the carvedilol arm, they will be prescribed to take carvedilol 12.5 mg for 12 months daily, and they will be seen in clinic at 4 weeks, at 6 and 12 months to see how they progress. Participants will also be asked to take part in two qualitative interviews so that we understand how they feel

about being in the trial. This will be after randomisation and the second one from 6-12 months. If participants are randomised to the variceal band ligation arm, they will have up to 5 endoscopy band ligations over the 12 months, and the number of endoscopy visits will depend on how well the varices are eradicated. Participants will also be asked to take part in two qualitative interviews so that we understand how they feel about being in the trial. This will be after randomisation and the second one from 6-12 months.

What are the possible benefits and risks of participating?

Although there may be no direct benefits to participants for taking part in this study, the results of the trial will lead to the best treatment being offered to prevent bleeding in patients with liver cirrhosis and medium or large oesophageal varices. Variceal banding has been used for nearly 30 years and is generally very safe. As banding is an endoscopic procedure about 1 in 10 patients may experience discomfort and find it difficult to tolerate the procedure. Infrequent complications include bleeding affecting about 1 in 20 patients, and a very small risk of causing narrowing of the gullet making it difficult to swallow or causing a tear in the gullet (perforation). Carvedilol is a medication that was initially developed to treat high blood pressure and some forms of heart disease. As with any drug, there are potential minor side effects that affect around half of patients, but serious complications are very rare. The side effects of carvedilol which can be difficult to tolerate in about 1 in 10 patients include: shortness of breath, low blood pressure causing dizziness, and upset stomach. Other less common side effects include abnormal vision, bradycardia (slow heart rate), asthenia (fatigue), and impotence. We will carefully monitor any side effects and take action where needed. It is important that medium to large varices are treated so if participants are not able to tolerate variceal banding or carvedilol, they will be offered an alternative treatment. All the tests participants will receive and procedures that will be undertaken are part of normal clinical care for patients with oesophageal varices. There will be an independent safety committee that will oversee the trial.

Where is the study run from?

The trial is run from Birmingham Clinical Trials Unit and at least 66 hospitals/ Health boards around the UK will be involved in recruitment.

When is the study starting and how long is it expected to run for?

March 2018 to February 2024

Who is funding the study?

National Institute for Health Research Health Technology Assessment Programme (UK)

Who is the main contact?

Lisa Holden

calibretrial@trials.bham.ac.uk

Study website

<https://www.birmingham.ac.uk/calibretrial>

Contact information

Type(s)

Scientific

Contact name

Dr Lisa Holden

Contact details

Birmingham Clinical Trials Unit (BCTU)
Institute of Applied Health Research
College of Medical and Dental Sciences
Public Health Building
University of Birmingham
Edgbaston
Birmingham
United Kingdom
B15 2TT
+44 (0)121 414 7943
l.m.holden@bham.ac.uk

Additional identifiers

EudraCT/CTIS number

2018-002488-24

IRAS number

ClinicalTrials.gov number

Protocol/serial number

RG_17-229

Study information

Scientific Title

CArvediloL versus variceal Band ligation in primary pREvention of variceal bleeding in liver cirrhosis

Acronym

CALIBRE

Study hypothesis

To compare carvedilol versus variceal band ligation in preventing any variceal bleeding within 1 year of randomisation in patients with cirrhosis and medium to large oesophageal varices that have never bled.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 19/10/2018 NHS HRA North East - York REC, (Priory Street Centre, Priory Street, York, YO1 6ET; 0207 104 8079; nrescommittee.northeast-york@nhs.net), ref: 18/NE/0296.
CTA MHRA approval granted 20/09/2018.

Study design

Interventional prospective multicentre pragmatic open-label two-arm randomised controlled parallel group trial with internal pilot

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

<https://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/portfolio-v/CALIBRE/investigators/documentation.aspx>

Condition

Variceal bleeding in liver cirrhosis

Interventions

After participant eligibility has been confirmed and informed consent has been received, the participant can be randomised into the trial. A Randomisation Form will be provided to investigators and will be used to collate the necessary information prior to randomisation. All questions and data items on the Randomisation Form must be answered before a Trial Number can be given. If data items are missing, randomisation will be stopped, but can be restarted once the information is available. Only when all eligibility criteria and baseline data items have been provided will a Trial Number be allocated. Participants will be randomised at the level of the individual in a 1:1 ratio to either treatment with 12.5 mg carvedilol once daily for 12 months or variceal band ligation. Both of these treatments will start on the same day as randomisation, or as soon as possible after. Patients randomised in clinic after the diagnostic endoscopy will be started on carvedilol 12.5 mg once daily for 12 months or variceal band ligation within two weeks of randomisation. A minimisation algorithm will be used within the online randomisation system to ensure balance in the treatment allocation over the following variables: presence or absence of hepatic decompensation (ascites or encephalopathy), size of the largest varix (Grade II, or Grade III), age of patient at randomisation (18-50, 51-70, >70), and presence or absence of alcohol related liver disease. A 'random element' will be included in the minimisation algorithm, so that each patient has a probability (unspecified here), of being randomised to the opposite treatment that they would have otherwise received. Full details of the randomisation specification will be stored in a confidential document at BCTU. Participants will be in the study for a total duration of 12 months from the point of randomisation.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Carvedilol

Primary outcome measure

Any variceal bleeding within 12 months of randomisation, assessed through endoscopy for the variceal band ligation (VBL) and through observation for the carvedilol arm at 4 weeks and after 6 and 12 months

Secondary outcome measures

1. Time to first variceal bleed in days from randomisation, assessed through endoscopy for the variceal band ligation (VBL) and through observation for the carvedilol arm at 4 weeks and after 6 and 12 months
2. Mortality at 12 months from randomisation, assessed using medical records and staff notification after 6 and 12 months:
 - 2.1. All-cause mortality
 - 2.2. Liver-related mortality
 - 2.3. Cardiovascular mortality
3. Transplant-free survival at 12 months after randomisation, assessed using medical records and staff notification after 6 and 12 months
4. Adverse events related to treatment up to 12 months after randomisation, assessed using follow-up case report forms (CRFs), medical records and staff notification after 6 and 12 months:
 - 4.1. Dysphagia
 - 4.2. Symptomatic hypotension
 - 4.3. Dyspnoea
 - 4.4. Gastrointestinal upset
5. Other complications of cirrhosis, assessed using follow-up case report forms (CRFs), medical records and staff notification after 6 and 12 months:
 - 5.1. New onset ascites
 - 5.2. New onset encephalopathy
 - 5.3. Spontaneous bacterial peritonitis
 - 5.4. Hepatocellular carcinoma
 - 5.5. Any renal dysfunction
6. Health-related quality of life, assessed using the EQ-5D-5L at the baseline and after 6 and 12 months
7. Use of healthcare resources, cost and cost-effectiveness, based on:
 - 7.1. Cost per variceal bleeding avoided within 12 months of randomisation, assessed using a follow-up CRF
 - 7.2. Cost per Quality-Adjusted Life Year (QALY) estimated using the EQ-5D-5L
 - 7.3. Cost per death avoided at 12 months, assessed using a follow-up CRF
8. Patient preferences, assessed using qualitative interviews that explore patients' experience of and preferences related to treatment (carvedilol or VBL), providing the basis to describe qualitatively patients' experience of the trial interventions. The first interview will be just after randomisation (ideally within 2 weeks) and the second will be 6-12 months after randomisation.
9. Use of alternative therapies, assessed using a follow-up CRF after 6 and 12 months
10. Crossover therapies, assessed using a follow-up CRF after 6 and 12 months

Overall study start date

01/03/2018

Overall study end date

29/02/2024

Eligibility

Participant inclusion criteria

1. Liver cirrhosis as defined clinically, radiologically (USS and transient elastography), or on histology
2. Medium varices (Grade II varices that do not flatten on air insufflation and do not occlude the lumen) and large varices (Grade III varices which are larger than Grade II varices and occupy the whole lumen) that have never bled as defined in the BSG guidelines
3. Aged 18 years or older

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

2630

Total final enrolment

266

Participant exclusion criteria

Current exclusion criteria as of 24/11/2021:

1. Age <18 years
2. Pregnant or lactating women
3. Known intolerance or contraindications to beta-blockers including asthma
4. Current or past history of non-selective beta-blocker use (such as carvedilol, nadolol or propranolol)
5. Current or history of variceal band ligation
6. Presence of malignancy or systemic disease that significantly affects 1-year survival
7. Unable to give informed consent
8. Diagnosed with acute alcoholic hepatitis at the point of randomisation
9. Patients with surgical or radiological portosystemic shunts such as transjugular portosystemic stent-shunt (TIPSS)
10. Previous organ transplantation

Previous exclusion criteria:

1. Pregnant or lactating women
2. Known allergy to carvedilol
3. Already on non-selective beta-blockers that could not be discontinued
4. Presence of malignancy or systemic disease that significantly affects 1-year survival

5. Unable to give informed consent
6. Contraindications to beta-blockers including asthma
7. Acute alcoholic hepatitis

Recruitment start date

22/01/2019

Recruitment end date

31/08/2022

Locations

Countries of recruitment

England

Northern Ireland

Scotland

United Kingdom

Wales

Study participating centre

Basildon and Thurrock University Hospital NHS Foundation Trust

Nethermayne

Basildon

United Kingdom

SS16 5NL

Study participating centre

Bradford Royal Infirmary

Duckworth Lane

Bradford

United Kingdom

BD9 6RJ

Study participating centre

University Hospital Coventry & Warwickshire NHS Trust

Clifford Bridge Road

Coventry

United Kingdom

CV2 2DX

Study participating centre

County Durham and Darlington NHS Foundation Trust

University Hospital of North Durham

North Road

Durham

United Kingdom

DH1 5TW

Study participating centre

The Newcastle upon Tyne Hospitals NHS Foundation Trust

Freeman Hospital

Newcastle

United Kingdom

NE7 7DN

Study participating centre

Gateshead Health NHS Foundation Trust

Queen Elizabeth Hospital

Sheriff Hill

Gateshead

United Kingdom

NE9 6SX

Study participating centre

Greater Glasgow and Clyde Health Board

GI Offices

4th Floor Walton Building

Glasgow Royal Infirmary

Castle Street

Glasgow

United Kingdom

G4 0SF

Study participating centre

Gloucestershire Hospitals NHS Foundation

Department of Hepatology

Orchard Centre

Gloucestershire Royal Hospital

Gloucester

United Kingdom

GL1 3NN

Study participating centre
Hull University Teaching Hospitals
Gastroenterology and Hepatology Research Department
Level 8 Alderson House
Hull Royal Infirmary
Anlaby Road
Hull
United Kingdom
HU3 2JZ

Study participating centre
Imperial College Healthcare NHS Trust
Hepatology Clinical Research Facility
Liver & Anti-Viral Unit
Imperial College Healthcare NHS Trust
10th Floor
QEQM
St Mary's
South Wharf Road
London
United Kingdom
W2 1NY

Study participating centre
King's College Hospital
Denmark Hill
Brixton
London
United Kingdom
SE5 9RS

Study participating centre
University Hospitals of Leicester NHS Trust
Leicester Royal Infirmary,
Infirmary Square
Leicester
United Kingdom
LE1 5WW

Study participating centre
The Royal Wolverhampton Trust
New Cross Hospital

Wolverhampton
United Kingdom
WV10 0QP

Study participating centre

NHS Tayside
Ninewells Hospital
Dundee
United Kingdom
DD1 9SY

Study participating centre

Nottingham University Hospitals NHS Trust
Queen's Medical Centre
Derby Road
Nottingham
United Kingdom
NG7 2UH

Study participating centre

Portsmouth Hospitals NHS Trust
Queen Alexandra Hospital
Portsmouth
United Kingdom
PO6 3LY

Study participating centre

Royal Devon and Exeter NHS Foundation Trust
Department of Gastroenterology and Hepatology
Barrack Road
Exeter
United Kingdom
EX2 5DW

Study participating centre

Royal Free London
Institute of Liver and Digestive Health
Upper Third Floor
UCL Medical School Royal Free Campus

London
United Kingdom
NW3 2PF

Study participating centre
York Teaching Hospital NHS Foundation Trust
Scarborough Hospital
Woodlands Drive
Scarborough
United Kingdom
YO12 6QL

Study participating centre
South Tyneside District Hospital
Harton Lane
South Shields
United Kingdom
NE34 0PL

Study participating centre
York Teaching Hospital NHS Foundation Trust
York Hospital
Wigginton Road
York
United Kingdom
YO31 8HE

Study participating centre
Birmingham Heartlands Hospital
Bordesley Green E
Birmingham
United Kingdom
B9 5SS

Study participating centre
University Hospitals Birmingham
Liver Unit
Mindelsohn Way
Edgbaston

Birmingham
United Kingdom
B15 2TH

Study participating centre

NHS Lothian

Liver Unit
Royal Infirmary of Edinburgh
Little France
Edinburgh
United Kingdom
EH6 4SA

Study participating centre

Leeds Teaching Hospitals NHS Trust

Merville Building
St James's University Hospital
Beckett Street
Leeds
United Kingdom
LS9 7TF

Study participating centre

Aintree University Hospital NHS Foundation Trust

Lower Lane
Liverpool
United Kingdom
L9 7AL

Study participating centre

Belfast HSC Trust

Liver Unit
1st Floor
East Wing
Royal Victoria Hospital
Grosvenor Road
Belfast
United Kingdom
BT12 6BA

Study participating centre

Greater Glasgow & Clyde Health Board

Administration Block 2nd Floor
Queen Elizabeth University Hospital
1345 Govan Road
Glasgow
United Kingdom
G51 4TF

Study participating centre**NHS Grampian**

Aberdeen Royal Infirmary
Aberdeen
United Kingdom
AB25 2ZN

Study participating centre**Royal Liverpool and Broadgreen University Hospitals NHS Trust**

Link 5Z
Prescot Street
Liverpool
United Kingdom
L7 8XP

Study participating centre**University Hospital Southampton NHS Foundation Trust**

Tremona Road
Southampton
United Kingdom
SO16 6YD

Study participating centre**Cwm Taf University Health Board**

Singleton Hospital
Sketty Lane
Swansea
United Kingdom
SA2 8QA

Study participating centre**The Mid Yorks NHS Trust**

Pinderfields Hospital

Aberford Road
Wakefield
United Kingdom
WF1 4DG

Study participating centre
Cambridge University Hospitals NHS Foundation Trust
Liver Unit
Addenbrookes Hospital
Hills Road
Cambridge
United Kingdom
CB2 0QQ

Study participating centre
South Tees Hospital NHS Foundation Trust
Endoscopy Centre
James Cook University Hospital
Marton Road
Middlesbrough
United Kingdom
TS4 3BW

Study participating centre
University Hospitals Plymouth NHS Trust
Derriford Hospital
Crownhill Road
Plymouth
United Kingdom
PL6 8DH

Study participating centre
Oxford University Hospitals NHS Foundation Trust
John Radcliffe Hospital
Headley Way
Oxford
United Kingdom
OX3 9DU

Study participating centre

University Hospitals of Derby and Burton NHS Foundation Trust
Royal Derby Hospital
Uttoxeter Road
Derby
United Kingdom
DE22 3NE

Study participating centre
Cardiff and Vale University Health Board
Department of Gastroenterology and Hepatology
Ward A7
University Hospital of Wales
Health Park
Cardiff
United Kingdom
CF14 4XN

Study participating centre
Torbay and South Devon NHS Foundation Trust
Torbay Hospital
Loves Bridge
Torquay
United Kingdom
TQ2 7AA

Study participating centre
Royal Cornwall Hospital Trust
Department of Gastroenterology and Hepatology
Royal Cornwall Hospital
Treliske
Truro
United Kingdom
TR1 3LJ

Study participating centre
Barts Health NHS Trust
Hepatology Clinical research
Grahame Hayton Unit
Ambose King Centre
Royal London Hospital
Whitechapel Road

London
United Kingdom
E1 1BB

Study participating centre
Sandwell & West Birmingham Hospital NHS Trust
Dudley Road
Birmingham
United Kingdom
B18 7QH

Study participating centre
Sheffield Teaching Hospitals NHS Foundation Trust
Robert Hadfield Level 2
Northern General Hospital
Herries Road
Sheffield
United Kingdom
S5 7AU

Study participating centre
North Bristol NHS Trust
Southmead Hospital
Bristol
United Kingdom
BS10 5NB

Study participating centre
NHS Fife
Victoria Hospital
Hayfield Road
Kirkcaldy
United Kingdom
KY2 5AH

Study participating centre
St. George's University Hospitals NHS Foundation Trust
Blackshaw Road
London
United Kingdom
SW17 0QT

Study participating centre
Northumbria Healthcare Trust
North Tyneside Hospital
Rake Lane
South Shields
United Kingdom
NE29 8NH

Study participating centre
South Tyneside and Sunderland NHS Foundation Trust
South Tyneside Hospital
Harton Lane
South Shields
United Kingdom
NE34 0PL

Study participating centre
Wrightington, Wigan and Leigh NHS Foundation Trust
Royal Albert Edward Infirmary
Wigan lane
Wigan
United Kingdom
WN1 2NN

Study participating centre
Shrewsbury and Telford Hospitals NHS Trust
Royal Shrewsbury Hospital
Mytton Oak Road
Shrewsbury
United Kingdom
SY3 8XQ

Study participating centre
Guy's and St. Thomas NHS Foundation Trust
Guy's and St. Thomas Hospital
Westminster Bridge Road
London
United Kingdom
SE1 7EH

Study participating centre

Dudley Group of NHS Hospitals Foundation Trust

Russells Hall Hospital
Pensenett Road
Dudley
United Kingdom
DY1 2HQ

Study participating centre

Chelsea and Westminster Hospital Foundation Trust

Chelsea and Westminster Hospital
369 Fulham Road
Chelsea
London
United Kingdom
SW10 9NH

Study participating centre

Hampshire Hospitals NHS Foundation Trust

Aldermaston Road
Basingstoke
United Kingdom
RG24 9NA

Study participating centre

The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust

The Royal Bournemouth Hospital
Castle Lane East
Bournemouth
United Kingdom
BH7 7DW

Study participating centre

Cwm Taf Morgannwg University Health Board

Ynysmeurig House
Navigation Park
Abercynon
United Kingdom
CF45 4SN

Study participating centre
Salisbury NHS Foundation Trust
Salisbury District Hospital
Odstock Road
Salisbury
United Kingdom
SP2 8BJ

Study participating centre
South Tyneside and Sunderland NHS Foundation Trust
Kayll Road
Sunderland
United Kingdom
SR4 7TP

Study participating centre
Great Western Hospitals NHS Foundation Trust
Marlborough Road
Swindon
United Kingdom
SN3 6BB

Study participating centre
Walsall Healthcare NHS Trust
Off Moat Road
Walsall
United Kingdom
WS2 9PS

Sponsor information

Organisation
University of Birmingham

Sponsor details
University of Birmingham
Research & Governance
Aston Webb Building
Edgbaston
Birmingham
B15 2TT

Birmingham
England
United Kingdom
B15 2TT

Sponsor type

University/education

Website

<https://intranet.birmingham.ac.uk/finance/RSS/Research-Support-Group/Research-Governance/index.aspx>

ROR

<https://ror.org/03angcq70>

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Regular newsletters will keep collaborators informed of trial progress, and regular meetings will be held to report progress of the trial and to address any problems encountered in the conduct of the trial.

Results of this trial will be submitted for publication in a peer reviewed journal. The manuscript will be prepared by the CI or delegate and authorship will be determined by the trial publication policy. Participants will be informed of the outcome of the trial via a link to a preview of the publication. A lay summary will also be provided via email or posted to participants prior to

publication.

Any secondary publications and presentations prepared by Investigators must be reviewed and approved by the TMG. Manuscripts must be submitted to the TMG in a timely fashion and in advance of being submitted for publication, to allow time for review and resolution of any outstanding issues. Authors must acknowledge that the trial was performed with the support of the University of Birmingham. Intellectual property rights will be addressed in the Clinical Study Site Agreement or between Sponsor and site.

Intention to publish date

01/09/2025

Individual participant data (IPD) sharing plan

This trial will include optional consent to allow linkage to patient data available in NHS routine clinical datasets, including primary care data (e.g. Clinical Practice Research Datalink; CPRD, The Health Improvement Network; THIN, QResearch), secondary care data (Hospital Episode Statistics; HES) and mortality data from the Office of National Statistics (ONS) through NHS Digital and other central UK NHS bodies. The consent will also allow access to other new central UK NHS databases that may appear in the future. This will allow us to double check the main outcomes against routine data sources, and extend the follow-up of patients in the trial and collect long-term outcome and health resource usage data without needing further contact with the trial participants. This is important, as it will link a trial of treatments that may become a clinical standard of care to long-term outcomes that are routinely collected in clinical data, but which may not be collected during the period of the trial.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	01/04/2019	24/05/2019	Yes	No
HRA research summary			28/06/2023	No	No